Home LiteratureArticle Details
PMID: 14580257 Published · ppublish English Journal Article Research Support, Non-U.S. Gov't Research Support, U.S. Gov't, Non-P.H.S.

E-cadherin expression in primary carcinomas of the breast and its distant metastases.

Breast cancer research : BCR ·Vol. 5 ·No. 6 ·2003-00-00 ·Pages R217-22

Kowalski PJ, Rubin MA, Kleer CG

Abstract

Aberrant expression of E-cadherin has been associated with the development of metastases in patients with breast cancer. Even though the expression of E-cadherin has been studied in primary breast tumors, little is known about its expression at the distant metastatic sites. We investigate the relationship between E-cadherin expression in primary breast carcinoma and their distant, non-nodal metastases. Immunohistochemical analysis of E-cadherin was performed in tissues from 30 patients with primary invasive breast carcinoma and their distant metastases. E-cadherin expression was evaluated as normal or aberrant (decreased when compared with normal internal positive controls, or absent). Twenty-two (73%) invasive carcinomas were ductal, and eight (27%) were lobular. Of the primary invasive ductal carcinomas, 55% (12/22) had normal E-cadherin expression and 45% (10/22) had aberrant expression. All of the metastases expressed E-cadherin with the same intensity as (12 tumors) or with stronger intensity than (10 tumors) the corresponding primaries. Of the invasive lobular carcinomas, one of eight (12%) primary carcinomas and none of the metastases expressed E-cadherin in the cell membranes, but they accumulated the protein in the cytoplasm. Aberrant E-cadherin expression is frequent in invasive ductal carcinomas that progress to develop distant metastases. Distant metastases consistently express E-cadherin, often more strongly than the primary tumor. Invasive lobular carcinomas have a different pattern of E-cadherin expression, suggesting a different role for E-cadherin in this form of breast carcinoma.

MeSH Terms
Adult Aged Aged, 80 and over Breast/chemistry,pathology Breast Neoplasms/metabolism,pathology Cadherins/biosynthesis Female Humans Immunohistochemistry Middle Aged Neoplasm Metastasis
Chemicals
Cadherins
Authors & Affiliations
3 authors, click to expand affiliations / ORCID
Kowalski Paul J
Department of Pathology and Comprehensive Cancer Center, University of Michigan Medical School, Ann Arbor, Michigan, USA.
Rubin Mark A
Kleer Celina G
References (33)
33 references, click to expand
  1. Epithelial (E-) and placental (P-) cadherin cell adhesion molecule expression in breast carcinoma.
    J Pathol. 1993 Feb;169(2):245-50 PMID: 8383197
  2. Decreased E-cadherin expression is associated with poor prognosis in patients with prostate cancer.
    Cancer Res. 1994 Jul 15;54(14):3929-33 PMID: 7518346
  3. Expression of E-cadherin cell adhesion molecules in human breast cancer tissues and its relationship to metastasis.
    Cancer Res. 1993 Apr 1;53(7):1696-701 PMID: 8453644
  4. Correlation of E-cadherin expression with differentiation grade and histological type in breast carcinoma.
    Am J Pathol. 1993 Apr;142(4):987-93 PMID: 7682767
  5. Level of expression of E-cadherin mRNA in colorectal cancer correlates with clinical outcome.
    Br J Cancer. 1995 Mar;71(3):614-6 PMID: 7880746
  6. Anomalous expression of P-cadherin in breast carcinoma. Correlation with E-cadherin expression and pathological features.
    Am J Pathol. 1995 Mar;146(3):605-12 PMID: 7534041
  7. Frequent alterations in E-cadherin and alpha- and beta-catenin expression in human breast cancer cell lines.
    Oncogene. 1995 Oct 5;11(7):1319-26 PMID: 7478552
  8. Removal of sialic acid from the surface of human MCF-7 mammary cancer cells abolishes E-cadherin-dependent cell-cell adhesion in an aggregation assay.
    In Vitro Cell Dev Biol Anim. 1995 Sep;31(8):633-9 PMID: 8528519
  9. E-cadherin is a tumour/invasion suppressor gene mutated in human lobular breast cancers.
    EMBO J. 1995 Dec 15;14(24):6107-15 PMID: 8557030
  10. E-cadherin relates to EGFR expression and lymph node metastasis in primary breast carcinoma.
    Br J Cancer. 1996 Oct;74(8):1237-41 PMID: 8883410
  11. E-cadherin is inactivated in a majority of invasive human lobular breast cancers by truncation mutations throughout its extracellular domain.
    Oncogene. 1996 Nov 7;13(9):1919-25 PMID: 8934538
  12. Beta-catenin as oncogene: the smoking gun.
    Science. 1997 Mar 21;275(5307):1752-3 PMID: 9122680
  13. Relation between aberrant alpha-catenin expression and loss of E-cadherin function in prostate cancer.
    Int J Cancer. 1997 Aug 22;74(4):374-7 PMID: 9291424
  14. Simultaneous loss of E-cadherin and catenins in invasive lobular breast cancer and lobular carcinoma in situ.
    J Pathol. 1997 Dec;183(4):404-11 PMID: 9496256
  15. E-cadherin and alpha-, beta-, and gamma-catenin protein expression in relation to metastasis in human breast carcinoma.
    J Pathol. 1998 Jul;185(3):262-6 PMID: 9771479
  16. E-cadherin mediates aggregation-dependent survival of prostate and mammary epithelial cells through the retinoblastoma cell cycle control pathway.
    J Biol Chem. 1999 Apr 2;274(14):9656-64 PMID: 10092652
  17. Re-expression of E-cadherin, alpha-catenin and beta-catenin, but not of gamma-catenin, in metastatic tissue from breast cancer patients [seecomments].
    J Pathol. 2000 Jan;190(1):15-9 PMID: 10640987
  18. Regulation of cadherin adhesive activity.
    J Cell Biol. 2000 Feb 7;148(3):399-404 PMID: 10662767
  19. Aberrant methylation of the estrogen receptor and E-cadherin 5' CpG islands increases with malignant progression in human breast cancer.
    Cancer Res. 2000 Aug 15;60(16):4346-8 PMID: 10969774
  20. Posttranslational truncation and inactivation of human E-cadherin distinguishes prostate cancer from matched normal prostate.
    Cancer Res. 2001 Jan 15;61(2):489-92 PMID: 11212238
  21. Weekly trastuzumab and paclitaxel therapy for metastatic breast cancer with analysis of efficacy by HER2 immunophenotype and gene amplification.
    J Clin Oncol. 2001 May 15;19(10):2587-95 PMID: 11352950
  22. Persistent E-cadherin expression in inflammatory breast cancer.
    Mod Pathol. 2001 May;14(5):458-64 PMID: 11353057
  23. E-cadherin expression in prostate cancer: a broad survey using high-density tissue microarray technology.
    Hum Pathol. 2001 Jul;32(7):690-7 PMID: 11486167
  24. Epigenetic and genetic alterations of APC and CDH1 genes in lobular breast cancer: relationships with abnormal E-cadherin and catenin expression and microsatellite instability.
    Int J Cancer. 2003 Aug 20;106(2):208-15 PMID: 12800196
  25. A prognostic index in primary breast cancer.
    Br J Cancer. 1982 Mar;45(3):361-6 PMID: 7073932
  26. A long-term follow-up study of survival in stage I (T1N0M0) and stage II (T1N1M0) breast carcinoma.
    J Clin Oncol. 1989 Mar;7(3):355-66 PMID: 2918331
  27. Cadherin cell-adhesion molecules in human epithelial tissues and carcinomas.
    Cancer Res. 1989 Apr 15;49(8):2128-33 PMID: 2702654
  28. E-cadherin-mediated cell-cell adhesion prevents invasiveness of human carcinoma cells.
    J Cell Biol. 1991 Apr;113(1):173-85 PMID: 2007622
  29. Cell-cell contacts mediated by E-cadherin (uvomorulin) restrict invasive behavior of L-cells.
    J Cell Biol. 1991 Jul;114(2):319-27 PMID: 1649199
  30. Biosynthesis of the cell adhesion molecule uvomorulin (E-cadherin) in Madin-Darby canine kidney epithelial cells.
    J Biol Chem. 1991 Oct 15;266(29):19672-80 PMID: 1918074
  31. Pathological prognostic factors in breast cancer. I. The value of histological grade in breast cancer: experience from a large study with long-term follow-up.
    Histopathology. 1991 Nov;19(5):403-10 PMID: 1757079
  32. Differential loss of E-cadherin expression in infiltrating ductal and lobular breast carcinomas.
    Am J Pathol. 1993 Dec;143(6):1731-42 PMID: 8256859
  33. E-cadherin expression in primary and metastatic gastric cancer: down-regulation correlates with cellular dedifferentiation and glandular disintegration.
    Cancer Res. 1993 Apr 1;53(7):1690-5 PMID: 8453643
Article Info
Journal
Breast cancer research : BCR
Abbr.
Breast Cancer Res
ISSN
1465-542X
Published
2003-00-00
Epub
2003-00-26
Pages
R217-22
Language
English
Region
England
NLM ID
100927353
PMCID
PMC314411
Subset
IM
Analysis Services
Analysis Services

Contact

No. 2 Wenbo Road, Zhangqiu District, Jinan, Shandong

Qilu Normal University · Genelibs Bioinformatics Lab

750 Shunhua Rd, Jinan

2F, Bldg F, University Science Park

Tel: 0531-88819269

WeChat Official Account

Follow our WeChat subscription account for real-time updates and the latest in medical and biological research.


Business Email

E-mail: product@genelibs.com